---
title: "RAP-219’s Differentiated Mechanism Supports Unchanged $65 Price Target and Reiterated Buy on Rapport Therapeutics"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292891644.md"
description: "BTIG analyst Kambiz Yazdi reiterated a Buy rating on Rapport Therapeutics with an unchanged $65 price target. He cited RAP-219's differentiated non-dopaminergic mechanism for acute bipolar mania and significant unmet need as key drivers. Phase 2 data is expected in Q4 2026, supporting the valuation framework."
datetime: "2026-07-16T10:35:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292891644.md)
  - [en](https://longbridge.com/en/news/292891644.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292891644.md)
---

# RAP-219’s Differentiated Mechanism Supports Unchanged $65 Price Target and Reiterated Buy on Rapport Therapeutics

BTIG analyst Kambiz Yazdi maintained a Buy rating on Rapport Therapeutics, Inc. yesterday and set a price target of $65.00.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Kambiz Yazdi has given his Buy rating due to a combination of factors, including the significant unmet need in acute bipolar mania and the differentiated profile of RAP-219. He highlights that current therapies rely heavily on dopamine-based antipsychotics and older mood stabilizers, which leave a large subset of patients either inadequately controlled or unable to tolerate treatment, thereby creating a meaningful opportunity for a novel approach.

Yazdi emphasizes that RAP-219’s selective TARPγ8 modulation of AMPARs offers a mechanistically distinct, non-dopaminergic strategy that aligns with the neurocircuitry implicated in mania and could extend time to relapse due to its long half-life, a feature he views as commercially important. With Phase 2 data in bipolar mania expected in 4Q26 and a valuation framework combining a long-dated DCF and peak-sales multiple supporting an unchanged $65 price target, he sees a favorable risk–reward balance and thus reiterates a Buy rating on Rapport Therapeutics, Inc.

According to TipRanks, Yazdi is a 5-star analyst with an average return of 29.0% and a 69.23% success rate. Yazdi covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, AbSci, and Kazia Therapeutics.

### Related Stocks

- [RAPP.US](https://longbridge.com/en/quote/RAPP.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [PRAX.US](https://longbridge.com/en/quote/PRAX.US.md)
- [ABSI.US](https://longbridge.com/en/quote/ABSI.US.md)
- [KZIA.US](https://longbridge.com/en/quote/KZIA.US.md)

## Related News & Research

- [Renaissance Technologies LLC Sells 109,114 Shares of Rapport Therapeutics, Inc. $RAPP](https://longbridge.com/en/news/296325369.md)
- [Rapport Therapeutics CEO Abraham Ceesay sells 51,499 shares worth $2.41 million](https://longbridge.com/en/news/295706967.md)
- [This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday](https://longbridge.com/en/news/296231890.md)
- [Piper Sandler Reaffirms Their Buy Rating on Akebia Therapeutics (AKBA)](https://longbridge.com/en/news/296105482.md)
- [BrainStorm Cell Therapeutics GAAP EPS of -$0.35](https://longbridge.com/en/news/296069988.md)